Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02353598 · ClinicalTrials.gov registry record · Phase 1
A Study of Crenezumab in Participants With Mild to Moderate Alzheimer Disease
A Phase 1 study, sponsored by Genentech.
- Completed
- Registry status
- Phase 1
- Development phase
- 77
- Enrollment target
NCT02353598 is a Phase 1 study that has completed, run by Genentech. The registered enrollment target is 77 participants.
The verdict
NCT02353598, a Phase 1 study, has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 77 participants
- Enrollment target
Study Summary
This randomized, placebo-controlled, double-blind, parallel-arm study will evaluate the safety and tolerability of at least two dose levels of intravenous (IV) crenezumab in 24-72 participants with mild to moderate Alzheimer disease (AD) (mini-mental state examination \[MMSE\] 18 to 28 points, inclusive). An optional open-label extension (OLE) will be offered after the completion of initial double-blind stage.
Interventions
- DRUG Placebo
- DRUG Crenezumab dose level 1
- DRUG Crenezumab dose level 2
- DRUG Crenezumb dose level 3
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 77 participants |
| Start Date | 2015-02-26 |
| Est. Completion | 2019-03-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02353598
The ClinicalTrials.gov registry entry for NCT02353598 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 77 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT02353598 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02353598 about?
NCT02353598 is a clinical study titled "A Study of Crenezumab in Participants With Mild to Moderate Alzheimer Disease". This randomized, placebo-controlled, double-blind, parallel-arm study will evaluate the safety and tolerability of at least two dose levels of intravenous (IV) crenezumab in 24-72 participants with mild to moderate Alzheimer disease (AD) (mini-mental state examination \[MMSE\] 18 to 28 points, inclu...
What is the current status of trial NCT02353598?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 77 participants. The study started on 2015-02-26. Estimated completion is 2019-03-26.
What interventions are being tested in trial NCT02353598?
The interventions under investigation include: Placebo (DRUG), Crenezumab dose level 1 (DRUG), Crenezumab dose level 2 (DRUG), Crenezumb dose level 3 (DRUG).
Who is sponsoring clinical trial NCT02353598?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.